These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9499974)

  • 21. Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study.
    Poon AC; Forbes JE; Dart JK; Subramaniam S; Bunce C; Madison P; Ficker LA; Tuft SJ; Gartry DS; Buckley RJ
    Br J Ophthalmol; 2001 Dec; 85(12):1464-9. PubMed ID: 11734522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Advantages and limits of multiple grafts (third keratoplasty) under local cyclosporin 2%].
    Alalwani H; Omer Saleh B; Rocher N; Renard G; Bourges JL; Legeais JM
    J Fr Ophtalmol; 2010 Dec; 33(10):710-4. PubMed ID: 21093105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Penetrating keratoplasty in Asian eyes: the Singapore Corneal Transplant Study.
    Tan DT; Janardhanan P; Zhou H; Chan YH; Htoon HM; Ang LP; Lim LS
    Ophthalmology; 2008 Jun; 115(6):975-982.e1. PubMed ID: 18061267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Study of the efficacy of cyclosporine used in patients at high risk of keratograft rejection. Communication 2. Immunological treatment monitoring].
    Slepova OS; Bykovskaia GN; Makarov PV; Balaian TG; Oganesian OG; Iluridze SL
    Vestn Oftalmol; 2007; 123(4):19-22. PubMed ID: 17802755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty.
    Dhaliwal JS; Mason BF; Kaufman SC
    Cornea; 2008 May; 27(4):488-93. PubMed ID: 18434855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement of graft prognosis in penetrating normal-risk keratoplasty by HLA class I and II matching.
    Reinhard T; Böhringer D; Enczmann J; Kögler G; Mayweg S; Wernet P; Sundmacher R
    Eye (Lond); 2004 Mar; 18(3):269-77. PubMed ID: 15004576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effect of matching at the HLA-A and -B amino-acid triplet level on rejection-free clear graft survival in penetrating keratoplasty.
    Böhringer D; Reinhard T; Duquesnoy RJ; Böhringer S; Enczmann J; Lange P; Claas F; Sundmacher R
    Transplantation; 2004 Feb; 77(3):417-21. PubMed ID: 14966417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical aspects and treatment of immune reactions following penetrating normal-risk keratoplasty].
    Nguyen NX; Seitz B; Langenbucher A; Wenkel H; Cursiefen C
    Klin Monbl Augenheilkd; 2004 Jun; 221(6):467-72. PubMed ID: 15236106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chronic endothelial cell loss of the graft after penetrating keratoplasty: influence of endothelial cell migration from graft to host].
    Reinhard T; Böhringer D; Hüschen D; Sundmacher R
    Klin Monbl Augenheilkd; 2002 Jun; 219(6):410-6. PubMed ID: 12136435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor].
    Reinhard T; Sundmacher R; Godehardt E; Heering P
    Ophthalmologe; 1997 Jul; 94(7):496-500. PubMed ID: 9333395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis.
    Murphy GJ; Waller JR; Sandford RS; Furness PN; Nicholson ML
    Br J Surg; 2003 Jun; 90(6):680-6. PubMed ID: 12808614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M; Ben-Haim M; Zemer D; Malinger-Saavedra P; Rosin D; Kuriansky J; Lustig S; Shabtai EL; Shapira Z; Ayalon A
    Isr Med Assoc J; 2002 Nov; 4(11 Suppl):935-9. PubMed ID: 12455184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts.
    Unal M; Yücel I
    Br J Ophthalmol; 2008 Oct; 92(10):1411-4. PubMed ID: 18662913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognosis in repeat keratoplasty: per indication analysis in a large monocentric cohort].
    Böhringer D; Reinhard T
    Klin Monbl Augenheilkd; 2008 Jan; 225(1):50-6. PubMed ID: 18236370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention and treatment of corneal graft rejection: current practice patterns (2004).
    Randleman JB; Stulting RD
    Cornea; 2006 Apr; 25(3):286-90. PubMed ID: 16633028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cataract extraction and intraocular lens implantation after high-risk penetrating keratoplasty].
    Shi WY; Zeng QY; Li SW; Xie LX
    Zhonghua Yan Ke Za Zhi; 2003 Nov; 39(11):678-82. PubMed ID: 14766064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cyclosporin A eyedrops in the prevention of high-risk corneal graft rejection. II. Postoperative clinical results].
    Goichot-Bonnat L; Chemla P; Pouliquen Y
    J Fr Ophtalmol; 1987; 10(3):213-7. PubMed ID: 3301994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis.
    Perry HD; Doshi SJ; Donnenfeld ED; Bai GS
    Cornea; 2002 Mar; 21(2):161-3. PubMed ID: 11862086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic cyclosporin A in high failure risk, repeated corneal transplantation.
    Rumelt S; Bersudsky V; Blum-Hareuveni T; Rehany U
    Br J Ophthalmol; 2002 Sep; 86(9):988-92. PubMed ID: 12185123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The inhibition of keratoplasty rejection with topical cyclosporin A].
    Jai H; Zhang RX
    Zhonghua Yan Ke Za Zhi; 1991 Nov; 27(6):345-7. PubMed ID: 1818823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.